Sculptor Capital’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Sculptor Capital’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-82,100	Closed	-$271K	–	828
2020 Q4	$271K	Hold	82,100	–	–	﹤0.01%	434
2020 Q3	$272K	Hold	82,100	–	–	﹤0.01%	304
2020 Q2	$277K	Buy	82,100 +3,300	+4%	+$15.6K	﹤0.01%	238
2020 Q1	$302K	Sell	78,800 -145,000	-65%	-$674K	﹤0.01%	186
2019 Q4	$1.35M	Hold	223,800	–	–	0.01%	194
2019 Q3	$1.69M	Buy	223,800 +134,100	+149%	+$1.51M	0.02%	190
2019 Q2	$1.22M	Hold	89,700	–	–	0.01%	207
2019 Q1	$486K	Buy	+89,700	New	+$436K	﹤0.01%	188
2018 Q4	–	Sell	-16,300	Closed	-$133K	–	305
2018 Q3	$133K	Hold	16,300	–	–	﹤0.01%	247
2018 Q2	$159K	Buy	+16,300	New	+$167K	﹤0.01%	246
2017 Q4	–	Sell	-19,200	Closed	-$161K	–	212
2017 Q3	$161K	Buy	+19,200	New	+$203K	﹤0.01%	332
2017 Q2	–	Sell	-9,600	Closed	-$193K	–	415
2017 Q1	$193K	Buy	+9,600	New	+$191K	﹤0.01%	289

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IEFM

IQ EQ Fund Management Dublin 2, Ireland $1.32B AUM 31.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sculptor Capital's ZYNE Position: Q1 2021 in Review

Sculptor Capital sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q1 2021, closing a stake of 82,100 shares — an estimated $271K sold.

Sculptor Capital first reported a position in ZYNE in Q1 2017 and held it in 12 quarters. The position peaked at $1.69M in Q3 2019. 67 funds tracked by Wall St. Rank hold ZYNE as of Q1 2021.

Sculptor Capital reported no remaining Zynerba Pharmaceuticals, Inc position as of Q1 2021 after selling out during the quarter.
Sculptor Capital sold 82,100 Zynerba Pharmaceuticals, Inc shares in Q1 2021, an estimated $271K.
Sculptor Capital first reported a position in Zynerba Pharmaceuticals, Inc in Q1 2017 and held it in 12 quarters.
Sculptor Capital's Zynerba Pharmaceuticals, Inc position peaked at $1.69M in Q3 2019.
67 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q1 2021.

Based on Sculptor Capital's 13F filing for Q1 2021, filed 14 May 2021.